Optimizing ribavirin dosage: a new challenge to improve treatment efficacy in genotype 1 hepatitis C patients

Gastroenterol Clin Biol. 2009 Jun-Jul;33(6-7):580-3. doi: 10.1016/j.gcb.2009.04.009. Epub 2009 May 28.

Authors

V Loustaud-Ratti¹, F Stanke-Labesque, P Marquet, M-C Gagnieu, M Maynard, G Babany, C Trépo; French Ribavirin Group OPTIRIB

Affiliation

¹ Service de Médecine Interne et Fédération des Hépatites, CHU Dupuytren, 87042 Limoges cedex, France. veronique.loustaud-ratti@unilim.fr

PMID: 19481390
DOI: 10.1016/j.gcb.2009.04.009

No abstract available

MeSH terms

Anemia / chemically induced
Antiviral Agents / administration & dosage*
Antiviral Agents / adverse effects
Dose-Response Relationship, Drug
Drug Monitoring
Genotype
Hepacivirus / genetics
Hepatitis C, Chronic / drug therapy*
Humans
Ribavirin / administration & dosage*
Ribavirin / adverse effects

Substances

Antiviral Agents
Ribavirin